CRAPT-M: An effective prognostic predictor for hepatocellular carcinoma patients treated with locoregional-bevacizumab-immunotherapy

Table 1 The risk factors and corresponding scores

Risk factors	Score
CRP (mg/dL)
< 1.0	0
≥ 1.0	7
ALB (g/L)
< 35	0
≥ 35	5
PIVKA-II (mAU/mL)
< 1500	0
≥ 1500	5
TBIL (mg/dL)
< 1.0	0
≥ 1.0	4
MVI
No	0
Yes	4

CRP: C-reactive protein; ALB: Albumin; PIVKA-II: Protein induced by vitamin K absence or antagonist-II; TBIL: Total bilirubin; MVI: Macrovascular invasion.